About Event
Discover the Inaugural Dark Genome Target Discovery & Development Summit
Pioneering previously unexplored non-coding regions of the genome and non-canonical platforms, the inaugural Dark Genome Target Discovery & Development Summit is the first and only industry-focused forum to shed light on novel targets and unlock therapeutic potential across a wealth of diseases.
Collaborate with industry peers from discovery, biology, -omics, data science, computational biology, bioinformatics, and AI as they mine repeat sequences for regulatory mechanisms, genomic instability, and tumor-specific antigens, validate proof-of-concept and disease specificity, while navigating drug development for a completely new area of targets.
5 Reasons You Can't Miss the World’s First Industry-Dedicated Dark Genome Summit
Shed light on the dark genome’s role in disease biology and gain a deeper understanding of the mechanism of regulatory elements, retroviruses, and epigenomics to gauge protein-structure function and altered expression in different indications with the Massachusetts Institute of Technology, HERVolution, and NYU Medical Lab
Analyze multiomic data across the genomic, transcriptomic, and proteomic levels, combined with computational screens and AI to discover disease-specific therapeutic targets with NextRNA, Nucleome, Immatics, and CAMP4 Therapeutics
Equip assay development, bioinformatics, and machine learning to select optimal targets and ensure robust validation of safe and effective therapeutic targets with Mnemo Therapeutics and ROME Therapeutics
Advance and optimize platforms and technologies to guide end-to-end target discovery, selection, and validation while screening large single-cell and spatial datasets with Caeruleus Genomics and Regeneron
Turbocharge smooth drug development by navigating challenges in modality and indication selection, preclinical models, funding, and regulatory paths to guarantee a smooth path to the clinic and translatability with HAYA Therapeutics and PDC*line Pharma
Who Will Be Joining Us?
